论文部分内容阅读
目的检测Siglec-1(CD169)在原发性胆汁性肝硬化(PBC)患者外周血单核细胞上的蛋白表达,并探讨其与原发性胆汁性肝硬化发生发展的作用及临床意义。方法流式细胞术检测35例原发性胆汁性肝硬化患者及35例健康对照者、35例肝炎后肝硬化对照者外周血CD14CD169双阳性细胞的表达率;生化常规测定所有入选者血清生化指标水平。结果流式细胞术检测结果显示:原发性胆汁性肝硬化组外周血CD14CD169双阳性率为(13.0±2.2)%,显著高于健康对照组(1.0±0.2)%,及肝炎后肝硬化对照组(4.1±0.4)%,差异具有统计学意义(P<0.01)。并且Siglec-1表达与GGT(r=0.44,P<0.01)和ALP水平(r=0.33,P<0.05)密切相关。结论原发性胆汁性肝硬化患者单核细胞表面siglec-1蛋白表达显著增高,说明原发性胆汁性肝硬化患者外周血单核细胞已经发生巨噬细胞化,单核巨噬细胞介导的免疫炎症反应在原发性胆汁性肝硬化发生发展过程中起重要作用。
Objective To detect the protein expression of Siglec-1 (CD169) on peripheral blood mononuclear cells in patients with primary biliary cirrhosis (PBC) and to explore the role and clinical significance of Siglec-1 (CD169) in the development and progression of primary biliary cirrhosis. Methods Flow cytometry was used to detect the expression of CD14CD169 double positive cells in peripheral blood of 35 patients with primary biliary cirrhosis and 35 healthy controls and 35 patients with posthepatitic cirrhosis. The biochemical indexes Level. Results The results of flow cytometry showed that the double positive rate of CD14CD169 in peripheral blood of primary biliary cirrhosis group was (13.0 ± 2.2)%, significantly higher than that of healthy control group (1.0 ± 0.2)%, and that of posthepatitic cirrhosis control Group (4.1 ± 0.4)%, the difference was statistically significant (P <0.01). Siglec-1 expression was closely related to GGT (r = 0.44, P <0.01) and ALP level (r = 0.33, P <0.05). Conclusion The expression of siglec-1 on the surface of mononuclear cells in patients with primary biliary cirrhosis is significantly increased, indicating that peripheral blood mononuclear cells from patients with primary biliary cirrhosis have macrophagecytes and monocyte-macrophage-mediated Immune inflammatory reaction plays an important role in the development of primary biliary cirrhosis.